<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754400</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-ACLF-02</org_study_id>
    <nct_id>NCT03754400</nct_id>
  </id_info>
  <brief_title>Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).</brief_title>
  <official_title>A Randomized Controlled Trial of Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AIM of the study is to study the efficacy of intravenous albumin and standard medical
      treatment as compared to standard medical treatment alone in ameliorating/preventing SIRS and
      improving survival at 28 days .The project will be conducted in ILBS from august 2018 to
      December 2019Concept is to understand the immunology, pathophysiology and effects of albumin
      in the management of ACLF for betterment of the patient's condition and early recovery.

      All ACLF patients will be included as per the inclusion and exclusion criteria , after taking
      informed consent from the patient or their relatives. Will be evaluated for the possible risk
      factors for the development of SIRS/sepsis in ACLF patients and possible beneficial factors
      for resolution of SIRS /sepsis in ACLF patients. The effects of albumin administration as per
      this protocol versus standard medical treatment alone will be reviewed If patient develops
      allergic reactions to albumin, fluid overload, albumin will be stopped and patient will be
      treated accordingly to medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant free survival in both groups</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant free survival in both groups.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence or resolution of infection in both groups</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence or resolution of infection in both groups</measure>
    <time_frame>14 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence or resolution of infection in both groups</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant with development of new organ failure in both groups.</measure>
    <time_frame>7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant with development of new organ failure in both groups.</measure>
    <time_frame>14 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant with development of new organ failure in both groups.</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in both groups.</measure>
    <time_frame>28 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute on Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotics, nutrition and supportive treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.</description>
    <arm_group_label>Albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Antibiotics, nutrition and supportive treatment</description>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years to 65 years

          2. ACLF patients

        Exclusion Criteria:

          1. Patients who have already received albumin in last 1 week

          2. Patients who require albumin like PICD (Paracentesis-Induced Circulatory Dysfunction)

             ,SBP (Spontaneous bacterial peritonitis),LVP(large volume
             paracentesis),HRS(hepatorenal syndrome)

          3. Not given consent

          4. Significant cardiopulmonary or structural heart disease/ CKD(chronic kidney diseses)
             /volume overload /upper GI bleed.

          5. Pregnant/ HIV / HCC &gt;2cm size

          6. Alcoholic hepatitis eligible for steroids

          7. Previous known allergic/adverse reaction to albumin

          8. Any clinical condition which the investigator considers would make the patient
             unsuitable for the trial

          9. Patients who will receive palliative treatment only during their hospital admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Rakesh Jagdish, MD</last_name>
    <phone>01146300000</phone>
    <email>dr.rkj.kapil@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 17, 2018</study_first_submitted>
  <study_first_submitted_qc>November 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

